Literature DB >> 25633812

Circulating microRNAs in aging.

Massimiliano Bonafè1, Fabiola Olivieri2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633812      PMCID: PMC4359295          DOI: 10.18632/oncotarget.3175

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


× No keyword cloud information.
Aging research is currently focusing on circulating functional markers that can help discriminate the mechanisms of physiological aging from those of age-related diseases (ARDs). The cellular model of choice for this type of studies, cell senescence, has been providing highly valuable information. Senescent cells are characterized by permanent cell cycle arrest and acquisition of a senescence-associated secretory phenotype (SASP) [1]. This identifiable secretome can propagate senescence to surrounding cells and contribute to inflamm-aging, the systemic pro-inflammatory drift that accompanies aging and ARDs [2]. Micro (mi)RNAs are short, single-stranded RNAs that are increasingly recognized as epigenetic regulators of gene expression, modulating all cell functions including senescence [3]. These mediators of epigenetic information, which are actively secreted by living cells and circulate in all body fluids, are extensively being investigated as potential ARD biomarkers [4]. Our group recently reported a senescence-related increase of plasma miR-126-3p in healthy aged individuals and increased miR-126-3p synthesis and secretion in endothelial cells undergoing senescence [5]. Interestingly, plasma from type 2 diabetes (T2D) patients and endothelial cells exposed to hyperglycemic media shared reduced miR-126-3p concentrations. We also found that senescent endothelial cells exhibit significant downregulation of miR-126-3p target SPRED-1, an inhibitor of angiogenic signaling [5]. Notably, hyperglycemic conditions hamper miR-126-3p/SPRED-1 axis modulation [5]. Overall, our investigations have provided some interesting insights: i) they have unveiled an endothelial epigenetic remodeling program aimed at maintaining vascular homeostasis during aging that can be monitored by circulating miR-126-3p; ii) they suggest that miR-126-3p may be one of the mechanisms by which loss of replicative and survival capacity is at least partly offset by cells undergoing replicative senescence; iii) they indicate that the miR-126-3p-dependent mechanism is blunted in endothelial cells exposed to high glucose concentrations, a phenomenon that is reminiscent of the increased risk of micro and macrovascular complications experienced by T2D patients; and iv) they extend and confirm the notion that miR-126-3p-related endothelial dysfunction can be studied in vitro through the mechanisms of endothelial cell senescence. MiR-126 has a role in the maintenance of endothelial integrity, enhancing endothelial function and promoting blood vessel formation [6]. Intriguingly, recent studies have identified it as a modulator of inflammation and innate immune response, targeting some components of the nuclear factor (NF)-kB pathway, the master regulator of the pro-inflammatory program [7]. Our data therefore also provide proof of principle that miRNAs can be active components of the senescent endothelial cell secretome and that senescence-associated miRNAs (SA-miRNAs) may modulate the rate of inflamm-aging at the cellular and systemic level. In this framework, the compartmentalization of circulating miRNAs into different shuttles (proteins, lipoproteins, exosomes) is likely to constitute a biological communication code among tissues and organs that needs to be deciphered. Notably, miR-126 shuttled by exosomes is biologically active in target cells, strongly supporting the hypothesis that exosomal miRNAs have important roles in cellular cross-talk, potentially affecting ARDs progression. In the near future the identification of SASP-related miRNAs (and of other non-coding RNAs) and their specific shuttles, an aspect that has not yet been extensively investigated, is expected not only to help clarify the complex mechanisms of aging, but also to enable prediction or early diagnosis of the major ARDs and ultimately to inspire innovative strategies to delay their onset.
  7 in total

Review 1.  Inflamm-aging. An evolutionary perspective on immunosenescence.

Authors:  C Franceschi; M Bonafè; S Valensin; F Olivieri; M De Luca; E Ottaviani; G De Benedictis
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

Review 2.  Effect of aging on microRNAs and regulation of pathogen recognition receptors.

Authors:  Fabiola Olivieri; Antonio Domenico Procopio; Ruth R Montgomery
Journal:  Curr Opin Immunol       Date:  2014-04-25       Impact factor: 7.486

Review 3.  MicroRNAs as a novel cellular senescence regulator.

Authors:  Feng-Jiao Liu; Tie Wen; Ling Liu
Journal:  Ageing Res Rev       Date:  2011-06-13       Impact factor: 10.895

4.  The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis.

Authors:  Shusheng Wang; Arin B Aurora; Brett A Johnson; Xiaoxia Qi; John McAnally; Joseph A Hill; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Dev Cell       Date:  2008-08       Impact factor: 12.270

5.  Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells.

Authors:  Fabiola Olivieri; Massimiliano Bonafè; Liana Spazzafumo; Mirko Gobbi; Francesco Prattichizzo; Rina Recchioni; Fiorella Marcheselli; Lucia La Sala; Roberta Galeazzi; Maria Rita Rippo; Gianluca Fulgenzi; Sabrina Angelini; Raffaella Lazzarini; Anna Rita Bonfigli; Francesca Brugè; Luca Tiano; Stefano Genovese; Antonio Ceriello; Massimo Boemi; Claudio Franceschi; Antonio Domenico Procopio; Roberto Testa
Journal:  Aging (Albany NY)       Date:  2014-09       Impact factor: 5.682

6.  A complex secretory program orchestrated by the inflammasome controls paracrine senescence.

Authors:  Juan Carlos Acosta; Ana Banito; Torsten Wuestefeld; Athena Georgilis; Peggy Janich; Jennifer P Morton; Dimitris Athineos; Tae-Won Kang; Felix Lasitschka; Mindaugas Andrulis; Gloria Pascual; Kelly J Morris; Sadaf Khan; Hong Jin; Gopuraja Dharmalingam; Ambrosius P Snijders; Thomas Carroll; David Capper; Catrin Pritchard; Gareth J Inman; Thomas Longerich; Owen J Sansom; Salvador Aznar Benitah; Lars Zender; Jesús Gil
Journal:  Nat Cell Biol       Date:  2013-06-16       Impact factor: 28.824

7.  The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids.

Authors:  Judith Agudo; Albert Ruzo; Navpreet Tung; Hélène Salmon; Marylène Leboeuf; Daigo Hashimoto; Christian Becker; Lee-Ann Garrett-Sinha; Alessia Baccarini; Miriam Merad; Brian D Brown
Journal:  Nat Immunol       Date:  2013-11-24       Impact factor: 25.606

  7 in total
  10 in total

1.  Gastric bypass surgery with exercise alters plasma microRNAs that predict improvements in cardiometabolic risk.

Authors:  Y O Nunez Lopez; P M Coen; B H Goodpaster; A A Seyhan
Journal:  Int J Obes (Lond)       Date:  2017-03-27       Impact factor: 5.095

2.  miR-126-3p and miR-21-5p as Hallmarks of Bio-Positive Ageing; Correlation Analysis and Machine Learning Prediction in Young to Ultra-Centenarian Sicilian Population.

Authors:  Giulia Accardi; Filippa Bono; Giuseppe Cammarata; Anna Aiello; Maria Trinidad Herrero; Riccardo Alessandro; Giuseppa Augello; Ciriaco Carru; Paolo Colomba; Maria Assunta Costa; Immaculata De Vivo; Mattia Emanuela Ligotti; Alessia Lo Curto; Rosa Passantino; Simona Taverna; Carmela Zizzo; Giovanni Duro; Calogero Caruso; Giuseppina Candore
Journal:  Cells       Date:  2022-04-30       Impact factor: 7.666

3.  Coronary artery calcifications predict long term cardiovascular events in non diabetic Caucasian hemodialysis patients.

Authors:  Annalisa Noce; Maria Paola Canale; Ambrogio Capria; Valentina Rovella; Manfredi Tesauro; Giorgio Splendiani; Margherita Annicchiarico-Petruzzelli; Micol Manzuoli; Giovanni Simonetti; Nicola Di Daniele
Journal:  Aging (Albany NY)       Date:  2015-04       Impact factor: 5.682

4.  Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer?

Authors:  Christiane Margue; Susanne Reinsbach; Demetra Philippidou; Nicolas Beaume; Casandra Walters; Jochen G Schneider; Dorothée Nashan; Iris Behrmann; Stephanie Kreis
Journal:  Oncotarget       Date:  2015-05-20

Review 5.  Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?

Authors:  Cristina Sorina Cătană; George A Calin; Ioana Berindan-Neagoe
Journal:  Front Med (Lausanne)       Date:  2015-12-15

6.  Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma.

Authors:  Tomohiro Fujiwara; Koji Uotani; Aki Yoshida; Takuya Morita; Yutaka Nezu; Eisuke Kobayashi; Akihiko Yoshida; Takenori Uehara; Toshinori Omori; Kazuhisa Sugiu; Tadashi Komatsubara; Ken Takeda; Toshiyuki Kunisada; Machiko Kawamura; Akira Kawai; Takahiro Ochiya; Toshifumi Ozaki
Journal:  Oncotarget       Date:  2017-05-16

7.  Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?

Authors:  Marianna Mariani; Domenico Mattiucci; Elisa Rossi; Valeria Mari; Erico Masala; Angelica Giuliani; Valeria Santini; Fabiola Olivieri; Elena Marinelli Busilacchi; Stefania Mancini; Attilio Olivieri; Antonella Poloni
Journal:  Front Oncol       Date:  2020-11-20       Impact factor: 6.244

8.  Elevated and Correlated Expressions of miR-24, miR-30d, miR-146a, and SFRP-4 in Human Abdominal Adipose Tissue Play a Role in Adiposity and Insulin Resistance.

Authors:  Yury O Nunez Lopez; Gabriella Garufi; Magdalena Pasarica; Attila A Seyhan
Journal:  Int J Endocrinol       Date:  2018-03-12       Impact factor: 3.257

Review 9.  Comprehensive analysis on diagnostic value of circulating miRNAs for patients with ovarian cancer.

Authors:  Huiqing Wang; Tingting Wang; Wenpei Shi; Yuan Liu; Lizhang Chen; Zhanzhan Li
Journal:  Oncotarget       Date:  2017-05-24

10.  Circulating miR-3659 may be a potential biomarker of dyslipidemia in patients with obesity.

Authors:  Liu Miao; Rui-Xing Yin; Shang-Ling Pan; Shuo Yang; De-Zhai Yang; Wei-Xiong Lin
Journal:  J Transl Med       Date:  2019-01-14       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.